{"id":124000,"date":"2018-04-16T14:36:51","date_gmt":"2018-04-16T18:36:51","guid":{"rendered":"https:\/\/www.bu.edu\/sph\/?page_id=124000"},"modified":"2024-06-01T01:52:38","modified_gmt":"2024-06-01T05:52:38","slug":"private-sector-collaborations-with-academic-public-health-opportunities-and-challenges","status":"publish","type":"conversation","link":"https:\/\/www.bu.edu\/sph\/conversations\/education\/private-sector-collaborations-with-academic-public-health-opportunities-and-challenges\/","title":{"rendered":"Private-Sector Collaborations with Academic Public Health: Opportunities and Challenges"},"content":{"rendered":"<p><strong>Tuesday, October 2, 2018<\/strong><\/p>\n<p>8:30 a.m.\u20132 p.m.<\/p>\n<p>Hiebert Lounge<br \/>\n72 East Concord Street<br \/>\nBoston<\/p>\n<p>#BUSPHSymposia<\/p>\n<p>Public health aspires to generate the social, economic, and cultural conditions that can create health. This work, by definition, must involve collaboration across sectors. Historically, academic public health has achieved much success partnering with the public sector toward achieving its goals. Our partnership with the private sector, however, has been less straightforward. And yet, there seems to be little question that a genuine engagement with the private sector is necessary to generate the conditions that can foster a healthier world. This symposium aims to address the issues associated with private sector-academic public health collaborations with the goal of developing best practices that can maximize the benefits and limit the pitfalls.<\/p>\n<p>Cohosted with Boston University Questrom School of Business.<\/p>\n<hr \/>\n<div class=\"row\">\n<div class=\"col-sm-6\">\n<h6>CASE STUDIES\u2014ALCOHOL<\/h6>\n<div class=\"responsive-video\"><br \/>\n<iframe loading=\"lazy\" width=\"550\" height=\"310\" src=\"\/\/www.bu.edu\/buniverse\/interface\/embed\/embed.html?v=jwdwb0\" frameborder=\"0\"><\/iframe><br \/>\n<\/div>\n<\/div>\n<div class=\"col-sm-6\">\n<h6>CASE STUDIES\u2014E-CIGARETTES<\/h6>\n<div class=\"responsive-video\"><br \/>\n<iframe loading=\"lazy\" width=\"550\" height=\"310\" src=\"\/\/www.bu.edu\/buniverse\/interface\/embed\/embed.html?v=1AkpJQ0\" frameborder=\"0\"><\/iframe><br \/>\n<\/div>\n<\/div>\n<div class=\"col-sm-6\">\n<h6>CASE STUDIES\u2014NUTRITION<\/h6>\n<div class=\"responsive-video\"><br \/>\n<iframe loading=\"lazy\" width=\"550\" height=\"310\" src=\"\/\/www.bu.edu\/buniverse\/interface\/embed\/embed.html?v=1UXSLE0\" frameborder=\"0\"><\/iframe><br \/>\n<\/div>\n<\/div>\n<div class=\"col-sm-6\">\n<h6>SYNERGIES FOR IMPACT<\/h6>\n<div class=\"responsive-video\"><br \/>\n<iframe loading=\"lazy\" width=\"550\" height=\"310\" src=\"\/\/www.bu.edu\/buniverse\/interface\/embed\/embed.html?v=n9Cxq0\" frameborder=\"0\"><\/iframe><br \/>\n<\/div>\n<\/div>\n<\/div>\n<h3>Agenda<\/h3>\n<h5>8:00 a.m. \u2013 8:30 a.m.<\/h5>\n<h5><strong>Breakfast and Informal Greetings<\/strong><\/h5>\n<hr \/>\n<h5>8:30 a.m. \u2013 8:45 a.m.<\/h5>\n<h5><strong>OPENING REMARKS<\/strong><\/h5>\n<h6>Welcome<\/h6>\n<h5>Sandro Galea<\/h5>\n<p>Dean and Robert A. Knox Professor, Boston University School of Public Health<\/p>\n<h5>Michael McClean<\/h5>\n<p>Associate Dean for Research and Faculty Advancement and Professor, Environmental Health, Boston University School of Public Health<\/p>\n<hr \/>\n<h5>8:45 a.m. \u2013 9:45 a.m.<\/h5>\n<h5><strong>PART ONE: LEARNING FROM HISTORY\u2014CHALLENGES AND SUCCESSES IN PUBLIC-PRIVATE PARTNERSHIPS<\/strong><\/h5>\n<h6>Plenary<\/h6>\n<h5>Amy Lauren Fairchild<\/h5>\n<p>Associate Dean of Academic Affairs and Professor, School of Public Health, University of Texas A&amp;M<div class=\"bu_collapsible_container \" aria-live=\"polite\" data-customize-animation=\"false\"><h6 class=\"bu_collapsible\" aria-expanded=\"false\"tabindex=\"0\" role=\"button\">Read More<\/h6><div class=\"bu_collapsible_section\" style=\"display: none;\"><\/p>\n<p><img loading=\"lazy\" src=\"https:\/\/www.bu.edu\/sph\/files\/2018\/06\/HEADSHOT-Fairchild-Web.png\" alt=\"HEADSHOT Fairchild Web\" class=\"alignleft size-full wp-image-127868\" width=\"100\" height=\"125\" \/>Amy Lauren Fairchild is Associate Dean of Academic Affairs and a professor in the School of Public Health at the University of Texas A&amp;M, and a historian who has worked in the field of public health ethics and policy. She approaches pressing dilemmas in the ethics and politics of contemporary public health debates from the perspective of history, with its broad focus on the social forces that produce disease, shape policy, and determine the societal responses to both. The central intellectual theme of her work has been to explore the functions and limits of the State with an emphasis on harm reduction and tobacco, privacy and surveillance, immigration and outbreaks, and fear and panic. She holds an MPH and a PhD from Columbia University.<\/p>\n<p><a href=\"https:\/\/twitter.com\/AmyLFairchild\">@AmyLFairchild<\/a><\/p>\n<p><span><\/div>\n<\/div>\n<\/span><\/p>\n<h6>Plenary<\/h6>\n<h5>Yao Sodahlon<\/h5>\n<p>Director, Mectizan Donation Program<div class=\"bu_collapsible_container \" aria-live=\"polite\" data-customize-animation=\"false\"><h6 class=\"bu_collapsible\" aria-expanded=\"false\"tabindex=\"0\" role=\"button\">Read More<\/h6><div class=\"bu_collapsible_section\" style=\"display: none;\"><\/p>\n<p><img loading=\"lazy\" src=\"https:\/\/www.bu.edu\/sph\/files\/2018\/06\/HEADSHOT-Sodahlon-Web.png\" alt=\"HEADSHOT Sodahlon Web\" class=\"alignleft size-full wp-image-127877\" width=\"100\" height=\"125\" \/>Yao Sodahlon is the director of the Mectizan Donation Program (MDP), and is responsible for the overall success of the program by ensuring that Mectizan\u00ae (ivermectin) reaches the millions of people who need it. He works closely with partners to shape strategies for the elimination of onchocerciasis (commonly known as river blindness) and lymphatic filariasis (commonly known as elephantiasis). Sodahlon joined the program in 2006 to manage the Mectizan (donated by Merck &amp; Co. Inc., Kenilworth, NJ, USA) for the control and elimination of river blindness and albendazole (donated by GSK, Brentford, UK), which is co-administered with Mectizan to eliminate lymphatic filariasis in African countries and Yemen where onchocerciasis is co-endemic. He is also responsible for monitoring the distribution of Mectizan to ensure that it is safely administered during mass drug administration.\u202fBefore Sodahlon joined the MDP, he worked in the ministry of health in Togo, his home country, as director of the Division of Clinical Laboratories (health system policy and development) and contributed to various communicable disease control programs (malaria, tuberculosis, schistosomiasis, and lymphatic filariasis). He also taught clinical parasitology at the Lom\u00e9 School of Medicine in Togo and consulted for WHO supporting African countries with malaria policies and drug monitoring. Sodahlon has authored and contributed to dozens of peer-reviewed articles on tropical disease and public health. He holds an MD from the University of Lom\u00e9, Togo; a diploma of clinical pathology from Louis Pasteur University of Strasbourg (France); and a master\u2019s degree in international health from Victor Segalen University of Bordeaux (France).<\/p>\n<p><a href=\"https:\/\/twitter.com\/YaoSodahlon\">@YaoSodahlon<\/a><\/p>\n<p><span><\/div>\n<\/div>\n<\/span><\/p>\n<hr \/>\n<h5>9:45 a.m. \u2013 10:00 a.m.<\/h5>\n<h5><strong>Break<\/strong><\/h5>\n<hr \/>\n<h5>10:00 a.m. \u2013 11:30 a.m.<\/h5>\n<h5><strong>PART TWO: CASE STUDIES\u2014CHALLENGES OR OPPORTUNITIES?<\/strong><\/h5>\n<h6>Alcohol and NCDs<\/h6>\n<h5>Scott Ratzan<\/h5>\n<p>Senior Fellow, Mossavar-Rahmani Center for Business &amp; Government, Harvard Kennedy School<div class=\"bu_collapsible_container \" aria-live=\"polite\" data-customize-animation=\"false\"><h6 class=\"bu_collapsible\" aria-expanded=\"false\"tabindex=\"0\" role=\"button\">Read More<\/h6><div class=\"bu_collapsible_section\" style=\"display: none;\"><img loading=\"lazy\" src=\"https:\/\/www.bu.edu\/sph\/files\/2018\/07\/scottratzan.png\" alt=\"\" class=\"alignleft size-full wp-image-129189\" width=\"100\" height=\"125\" \/><span>Scott Ratzan is a Senior Fellow at the Mossavar-Rahmani Center for Business and Government at Harvard Kennedy School. He has three decades of pioneering accomplishments nationally and globally in health communication, health literacy, and strategic diplomacy. Ratzan is the founding editor-in-chief of the\u00a0<\/span><em>Journal of Health Communication: International Perspectives<\/em><span>, established in 1995. Over the last five years at Anheuser-Busch InBev, he was the architect of a groundbreaking approach to help reduce harmful drinking. Termed the Global Smart Drinking Goals, the program is a 10-year, $1 billion multi-sectoral initiative, which includes the creation of a foundation with an independently led board of which Ratzan was founding president. Prior to joining AB InBev, he was vice president of global health at Johnson &amp; Johnson for 11 years, including time in Brussels as vice president of government affairs.\u00a0 Before his private-sector engagement, Ratzan worked at the US Agency for International Development in Washington, DC, designing the framework for the Bureau of Global Health\u2019s communication efforts. He launched his career in Boston, spending a decade in academia as a professor and founding director of the Tufts-Emerson Graduate Program in Health Communication. In addition to a number of publications in the health field, he is the coauthor of the definition of health literacy adopted by the US government and incorporated into the Affordable Care Act. Recently, he has served as co-chair of the UN Secretary General\u2019s Every Woman Every Child Innovation Working Group, as vice chair of the Business Industry Advisory Council\u2019s Health Committee to the Organisation for Economic Co-operation and Development, on the World Economic Forum Global Agenda Council on Well-Being and Mental Health, and on the US Centers for Disease Control and Prevention, Board of Scientific Counselors, Office of Infectious Diseases. His academic appointments include adjunct professor at Columbia University Mailman School of Public Health, Tufts University School of Medicine, and George Washington University School of Public Health. Ratzan holds an MD from the University of Southern California, an MPA from the Harvard Kennedy School, and an MA in communication from Emerson College.<\/span><span><\/div>\n<\/div>\n<\/span><\/p>\n<h5>Sally Casswell<\/h5>\n<p>Co-Director, SHORE\/Whariki Research Centre, College of Health, Massey University<div class=\"bu_collapsible_container \" aria-live=\"polite\" data-customize-animation=\"false\"><h6 class=\"bu_collapsible\" aria-expanded=\"false\"tabindex=\"0\" role=\"button\">Read More<\/h6><div class=\"bu_collapsible_section\" style=\"display: none;\"><\/p>\n<p><img loading=\"lazy\" src=\"https:\/\/www.bu.edu\/sph\/files\/2018\/06\/HEADSHOT-Casswell-Web.png\" alt=\"HEADSHOT Casswell Web\" class=\"alignleft size-full wp-image-127862\" width=\"100\" height=\"125\" \/>Sally Casswell is a professor of social and health research and the co-director of the SHORE and Whariki Research Centre, College of Health at Massey University, New Zealand. Her research interests are in social and public health policy, particularly in relation to alcohol. She has carried out research on the development and implementation of public policy at the national and community levels and in the evaluation of these initiatives. A focus for some years has been on the commercial marketing of alcohol products. She is involved in international alcohol policy as a member of the WHO Expert Advisory Panel on Drug Dependence and Alcohol Problems, and SHORE is a WHO Collaborating Centre. Professor Casswell also is actively involved with the non-governmental organization (NGO) sector as chair of GAPA (Global Alcohol Policy Alliance). She is a Fellow of the Royal Society of New Zealand and an Officer of the Order of New Zealand.<\/p>\n<p><a href=\"https:\/\/twitter.com\/MasseyUni\">@MasseyUni<\/a><\/p>\n<p><span><\/div>\n<\/div>\n<\/span><\/p>\n<h5>Moderator:\u00a0 Richard Saitz\u00a0(MED\u201987)<\/h5>\n<p>Chair and Professor, Community Health Sciences, Boston University School of Public Health<\/p>\n<h6>E-Cigarettes<\/h6>\n<h5>Derek Yach<\/h5>\n<p>President, Foundation for a Smoke-Free World<div class=\"bu_collapsible_container \" aria-live=\"polite\" data-customize-animation=\"false\"><h6 class=\"bu_collapsible\" aria-expanded=\"false\"tabindex=\"0\" role=\"button\">Read More<\/h6><div class=\"bu_collapsible_section\" style=\"display: none;\"><\/p>\n<p><img loading=\"lazy\" src=\"https:\/\/www.bu.edu\/sph\/files\/2018\/06\/HEADSHOT-Yach-Web.png\" alt=\"HEADSHOT Yach Web\" class=\"alignleft size-full wp-image-127880\" width=\"100\" height=\"125\" \/>Derek Yach, a global health expert and anti-smoking advocate for more than 30 years, is the president of the Foundation for a Smoke-Free World. Throughout his career, he has supported and led smoking cessation research and policy development, and has been a strong proponent of harm-reduction policies, calling for a greater emphasis on harm reduction as early as 2005. He is also a passionate advocate of health promotion and disease prevention, and is advancing his career\u2019s work at the Foundation for a Smoke-Free World. Yach is a former World Health Organization (WHO) cabinet director and executive director for noncommunicable diseases and mental health, where he was deeply involved with the development of the world\u2019s treaty on tobacco control, the Framework Convention on Tobacco Control. He is also the former chief health officer of the Vitality Group, executive director of the Vitality Institute, senior vice president of global health and agriculture policy at PepsiCo, director of global health at the Rockefeller Foundation, and a professor of global health at Yale University. Yach has authored or coauthored more than 250 peer-reviewed articles on global health, and has served on several advisory boards, including the World Economic Forum, Cornerstone Capital, and the Wellcome Trust. From 2007 to 2016, he served on the program advisory committee of the Clinton Global Initiative. Yach is a native of South Africa and holds an honorary DSc from Georgetown University, an MBChB from the University of Cape Town, a BSc (Hons Epi) from the University of Stellenbosch, and an MPH from the Johns Hopkins Bloomberg School of Public Health.<\/p>\n<p><a href=\"https:\/\/twitter.com\/swimdaily\"><span>@swimdaily<\/span><\/a><\/p>\n<p><span><\/div>\n<\/div>\n<\/span><\/p>\n<h5>Michael Siegel<\/h5>\n<p>Professor, Community Health Sciences, Boston University School of Public Health<\/p>\n<h5>Moderator: Craig Ross<\/h5>\n<p>Research Assistant Professor, Epidemiology, Boston University School of Public Health<\/p>\n<hr \/>\n<h5>11:30 a.m. \u2013 noon<\/h5>\n<h5><strong>Lunch<\/strong><\/h5>\n<hr \/>\n<h5>noon \u2013 12:45 p.m.<\/h5>\n<h6>Nutrition<\/h6>\n<h5>Dariush Mozaffarian<\/h5>\n<p>Jean Mayer Professor of Nutrition and Medicine and Dean, Friedman School of Nutrition Science and Policy, Tufts University<div class=\"bu_collapsible_container \" aria-live=\"polite\" data-customize-animation=\"false\"><h6 class=\"bu_collapsible\" aria-expanded=\"false\"tabindex=\"0\" role=\"button\">Read More<\/h6><div class=\"bu_collapsible_section\" style=\"display: none;\"><\/p>\n<p><img loading=\"lazy\" src=\"https:\/\/www.bu.edu\/sph\/files\/2018\/07\/Headshot-Mozaffarian.png\" alt=\"\" class=\"alignleft size-full wp-image-128783\" width=\"100\" height=\"125\" \/>Dariush Mozaffarian is a cardiologist, Jean Mayer Professor of Nutrition and Medicine, and Dean of the Friedman School of Nutrition Science and Policy at Tufts University. The oldest and most renowned graduate school of nutrition in North America, the Friedman School\u2019s mission is to produce trusted science, future leaders, and real-world impact. He has authored more than 300 scientific publications on the dietary priorities to reduce cardiovascular disease, diabetes, and obesity in the United States and globally, and on evidence-based systems innovations and policies to effectively reduce these burdens. Mozaffarian has served in numerous advisory roles, including for the US and Canadian governments, American Heart Association, Global Burden of Diseases study, World Health Organization, and United Nations. His work has been featured in the<span>\u00a0<\/span><em>New York Times<\/em>,<span>\u00a0<\/span><em>Washington Post<\/em>,<span>\u00a0<\/span><em>Wall Street Journal<\/em>, National Public Radio,<span>\u00a0<\/span><em>Time Magazine<\/em>, and many other media outlets. In 2016, Thomson Reuters named Mozaffarian as one of theWorld\u2019s Most Influential Scientific Minds. Mozaffarian holds a BS in biological sciences from Stanford University (Phi Beta Kappa), an MD from Columbia University (Alpha Omega Alpha), and clinical training in internal medicine and cardiovascular medicine from Stanford University and the University of Washington. He also holds an MPH from the University of Washington and a doctorate in public health from Harvard University. Before being appointed as Dean at Tufts in 2014, Mozaffarian was at Harvard Medical School and Harvard School of Public Health for a decade and clinically active in cardiology at Brigham and Women\u2019s Hospital. He is married, has three children, and actively trains as a Black Belt (second degree) in Taekwondo. The Friedman School pursues cutting-edge research and education from cell to society, including in molecular nutrition, human metabolism, data sciences, clinical trials, behavior change, community and organizational interventions, media and communication, food systems and sustainability, global food security, humanitarian crises, and food economics and policy. Friedman School graduates are active in academics, policy, advocacy, government, industry, public health, community service, and entrepreneurship. The School\u2019s unique breadth, engagement with the world, and entrepreneurial spirit make it a leading institution for nutrition education, research, and public impact.<\/p>\n<p><a href=\"https:\/\/twitter.com\/Dmozaffarian\">@Dmozaffarian<\/a><\/p>\n<p><span><\/div>\n<\/div>\n<\/span><\/p>\n<h5>Sherry L. Pagoto<\/h5>\n<p>Professor, Allied Health Sciences, University of Connecticut<div class=\"bu_collapsible_container \" aria-live=\"polite\" data-customize-animation=\"false\"><h6 class=\"bu_collapsible\" aria-expanded=\"false\"tabindex=\"0\" role=\"button\">Read More<\/h6><div class=\"bu_collapsible_section\" style=\"display: none;\"><\/p>\n<p><img loading=\"lazy\" src=\"https:\/\/www.bu.edu\/sph\/files\/2018\/06\/HEADSHOT-Pagoto-Web.png\" alt=\"HEADSHOT Pagoto Web\" class=\"alignleft size-full wp-image-127894\" width=\"100\" height=\"125\" \/>Sherry L. Pagoto is a professor in the Department of Allied Health Sciences at the University of Connecticut and a licensed clinical psychologist and director of the UConn Center for mHealth and Social Media. Pagoto is also the president of the Society of Behavioral Medicine and co-chair of the Indoor Tan-Free Skin Smart Campus Initiative. Her research focuses on leveraging technology in the development and delivery of behavioral interventions targeting diet, physical activity, and cancer prevention behaviors. She has had federal funding for her program of research for 14 consecutive years and has published 184 papers in peer-reviewed journals. Pagoto has received several awards for her work, including the UMass Medical School Women in Science and Health Achievement Award in 2015, the Obesity Society Pioneer in mHealth\/eHealth Award in 2014, the Society of Behavioral Medicine Early Career\/Young Investigator Award in 2006, and the Western Michigan University Distinguished Alumni Award in 2011. Devoted to science communication, she has more than 23,000 followers on Twitter and is a contributor to<span>\u00a0<\/span><em>US News &amp; World Report<\/em>,<span>\u00a0<\/span><em>Chronicle of Higher Education<\/em>,<span>\u00a0<\/span><em>STAT News<\/em>, and<span>\u00a0<\/span><em>Psychology Today<\/em>. Her work has been featured in major news outlets, including CNN, NPR, NBC News, ABC News, and<span>\u00a0<\/span><em>Good Morning America<\/em>.<\/p>\n<p><a href=\"https:\/\/twitter.com\/DrSherryPagoto\">@DrSherryPagoto<\/a><\/p>\n<p><span><\/div>\n<\/div>\n<\/span><\/p>\n<h5>Moderator:\u00a0Monica L. Wang<\/h5>\n<p>Assistant Professor, Community Health Sciences<span>, Boston University School of Public Health<\/span><\/p>\n<hr \/>\n<h5>12:45 p.m. \u2013 1:55 p.m.<\/h5>\n<h5><strong>PART THREE: SYNERGIES FOR IMPACT<\/strong><\/h5>\n<h6>A Focus on the Health Industry<\/h6>\n<h5>Gary Cohen (SPH\u201906)<\/h5>\n<p>Co-founder, President, and Chief Operating Officer, Humatics Corporation<div class=\"bu_collapsible_container \" aria-live=\"polite\" data-customize-animation=\"false\"><h6 class=\"bu_collapsible\" aria-expanded=\"false\"tabindex=\"0\" role=\"button\">Read More<\/h6><div class=\"bu_collapsible_section\" style=\"display: none;\"><img loading=\"lazy\" src=\"https:\/\/www.bu.edu\/sph\/files\/2018\/06\/HEADSHOT-Cohen-Web.png\" alt=\"HEADSHOT Cohen Web\" class=\"alignleft size-full wp-image-127865\" width=\"100\" height=\"125\" \/><span>Gary Cohen is the co-founder, president, and chief operating officer at Humatics Corporation, a Cambridge-headquartered company building ultra-precise \u201cmicrolocation\u201d sensors and analytics software intended to transform how people and machines locate, navigate, and collaborate in an increasingly connected world. Applications for the Humatics sensors and software include the measurement and analysis of human micro-movement, and the detection and treatment of conditions that impact human locomotion.\u202fCohen has more than 30 years of law and ethics experience representing pioneering life sciences companies, including roles at Foundation Medicine, a cancer personalized medicine company (where he was responsible for bioethics, law, and policy) and Millennium Pharmaceuticals (where he developed industry-leading bioethics, business ethics, and corporate social responsibility programs).\u202fEarlier in his career, Cohen was the\u202fJoe and Vi Jacobs Visiting Professor of Biotechnology Law and Ethics\u202fat the Keck Graduate Institute of Applied Life Sciences in Claremont, California. He holds an AB from Washington University in St. Louis; a JD from Columbia Law School; and an MPH from the Boston University School of Public Health, where he serves on the Dean\u2019s Advisory Board.<\/span><span><\/div>\n<\/div>\n<\/span><\/p>\n<h5>Travis McCready<\/h5>\n<p>President &amp; CEO, Massachusetts Life Sciences Center<div class=\"bu_collapsible_container \" aria-live=\"polite\" data-customize-animation=\"false\"><h6 class=\"bu_collapsible\" aria-expanded=\"false\"tabindex=\"0\" role=\"button\">Read More<\/h6><div class=\"bu_collapsible_section\" style=\"display: none;\"><\/p>\n<p><img loading=\"lazy\" src=\"https:\/\/www.bu.edu\/sph\/files\/2018\/06\/HEADSHOT-McCready-Web.png\" alt=\"HEADSHOT McCready Web\" class=\"alignleft size-full wp-image-127923\" width=\"100\" height=\"125\" \/>Travis McCready is the president and CEO of the Massachusetts Life Sciences Center, a $1 billion public\u2013private partnership with the mission of advancing the life sciences ecosystem in Massachusetts. He directs and oversees the center\u2019s investment strategy, including the agency\u2019s operations, programs, and partnerships. Previously, McCready served as the vice president for programs at the Boston Foundation, directing the Foundation\u2019s grants and community investment strategy to benefit the people of Greater Boston. He was the first executive director of the Kendall Square Association, responsible for growing the innovation economy of Kendall Square, one of the Commonwealth\u2019s most economically robust districts. McCready has held the COO and CFO positions at the Massachusetts Convention Center Authority, overseeing the operations and finances for three convention centers in Massachusetts. A native of Brooklyn, he began his career as a public schoolteacher in the Bronx, New York. McCready serves on the Trustee Boards of the American Repertory Theater in Cambridge, Beth Israel Deaconess Medical Center, the Conservation Law Foundation, the New England Advisory Council for the Federal Reserve Bank of Boston, and WBUR. He served on the Economic Development Planning Council under two governors, including co-chairing the subcommittee on innovation and entrepreneurship. McCready currently serves on the Massachusetts Digital Healthcare Council and the Advanced Manufacturing Collaborative. In 2017, he was named one of Boston\u2019s 50 most powerful people by the<span>\u00a0<\/span><em>Boston Business Journal<\/em>. McCready is a frequent speaker on economic development strategy as it relates to the convergence of private, public, and not-for-profit interests, and his blog,<span>\u00a0<\/span><em>Life Sciences Discourses<\/em>, has been recognized by<span>\u00a0<\/span><em>The Boston Globe<\/em>. McCready holds a BA from Yale University and a JD from the University of Iowa.<\/p>\n<p><a href=\"https:\/\/twitter.com\/MALifeSciences\"><span>@MALifeSciences<\/span><\/a><\/p>\n<p><span><\/div>\n<\/div>\n<\/span><\/p>\n<h5>Christine Lemke<\/h5>\n<p>Cofounder and President, Evidation Health<div class=\"bu_collapsible_container \" aria-live=\"polite\" data-customize-animation=\"false\"><h6 class=\"bu_collapsible\" aria-expanded=\"false\"tabindex=\"0\" role=\"button\">Read More<\/h6><div class=\"bu_collapsible_section\" style=\"display: none;\"><\/p>\n<p><img loading=\"lazy\" src=\"https:\/\/www.bu.edu\/sph\/files\/2018\/06\/HEADSHOT-Lemke-Web.png\" alt=\"HEADSHOT Lemke Web\" class=\"alignleft size-full wp-image-127942\" width=\"100\" height=\"125\" \/>Christine Lemke is the cofounder and president of Evidation\u202fHealth. Previously, Lemke was the cofounder and\u202fchief operating officer of Sense Networks, developers\u202fof the first machine learning platform for mobile phone\u202factivity data (exited to\u202fYP.com). She also held\u202fpositions at 3i Group (Paris) and Microsoft Xbox, and cofounded Chicago-based Channel IQ, a product\u202fanalytics platform. Lemke holds a BA from the\u202fUniversity of Washington and an MBA from HEC Paris.<\/p>\n<p><a href=\"https:\/\/twitter.com\/cklemke\"><span>@cklemke<\/span><\/a><\/p>\n<p><span><\/div>\n<\/div>\n<\/span><\/p>\n<h5>Mylea Charvat<\/h5>\n<p>CEO &amp; Founder, Savonix<div class=\"bu_collapsible_container \" aria-live=\"polite\" data-customize-animation=\"false\"><h6 class=\"bu_collapsible\" aria-expanded=\"false\"tabindex=\"0\" role=\"button\">Read More<\/h6><div class=\"bu_collapsible_section\" style=\"display: none;\"><\/p>\n<p><img loading=\"lazy\" src=\"https:\/\/www.bu.edu\/sph\/files\/2018\/06\/HEADSHOT-Charvat-Web.png\" alt=\"HEADSHOT Charvat Web\" class=\"alignleft size-full wp-image-127927\" width=\"100\" height=\"125\" \/>Mylea Charvat is the CEO and founder of Savonix. She is committed to advancing the integration of cognitive health data into mainstream healthcare, and works with global leaders to advance the integration of cognitive test data into mainstream health and wellness. Charvat became interested in the brain at age 13 when her grandmother began to suffer cognitive problems. A clinician with a business background, she was an early employee with Travelocity in the 1990s and went on to train as a clinical neuropsychologist and neuroscientist. Charvat founded Savonix in 2015. At Savonix, she drives strategy to address dementia globally with business and clinical leaders, and works as a domain expert in digital cognitive assessment, with partners from Boston University, to<span>\u00a0<\/span><em>Fortune 50<\/em><span>\u00a0<\/span>CEOs seeking to detect and prevent cognitive decline and dementia. Charvat has authored several peer-reviewed publications in mental health and neuroimaging. She is a contributor for<span>\u00a0<\/span><em>Psychology Today<\/em>, has written for<span>\u00a0<\/span><em>Tech Crunch<\/em><span>\u00a0<\/span>and<span>\u00a0<\/span><em>Huffington Post<\/em>, and has appeared as a subject matter expert at many conferences, including MedTech Showcase, the Atlantic Council, the National Institutes of Health (NIH), and the National Institute on Aging (NIA), and with the Duke Leadership Program. Charvat holds a PhD from Palo Alto University and completed her fellowship in clinical neuroscience at Stanford University School of Medicine. She has been a lecturer at Stanford University, the University of San Francisco, and San Francisco State University.<\/p>\n<p><a href=\"https:\/\/twitter.com\/MyleaCharvat\">@MyleaCharvat<\/a><\/p>\n<p><span><\/div>\n<\/div>\n<\/span><\/p>\n<h5>Philip R. Reilly<\/h5>\n<p>Venture Partner, Third Rock Ventures<div class=\"bu_collapsible_container \" aria-live=\"polite\" data-customize-animation=\"false\"><h6 class=\"bu_collapsible\" aria-expanded=\"false\"tabindex=\"0\" role=\"button\">Read More<\/h6><div class=\"bu_collapsible_section\" style=\"display: none;\"><img loading=\"lazy\" src=\"https:\/\/www.bu.edu\/sph\/files\/2018\/06\/HEADSHOT-Reilly-Web.png\" alt=\"HEADSHOT Reilly Web\" class=\"alignleft size-full wp-image-127873\" width=\"100\" height=\"125\" \/><span>Philip R. Reilly is a venture partner at Third Rock Ventures in Boston, Massachusetts. Trained in internal medicine and clinical genetics, he specializes in starting and launching companies to develop breakthrough therapies for heretofore untreatable genetic disorders. Among other roles, he has served on the boards of Edimer Pharmaceuticals and Lotus Tissue Repair, Inc. In 2010, he helped to found bluebird bio Inc., a gene therapy company; and from 2010 to 2012, he served as its chief medical officer. More recently, Reilly has been a founder of Voyager Therapeutics (which specializes in using the adeno-associated virus to treat disorders of the central nervous system) and Fulcrum Therapeutics, a company that focuses on gene regulation. Prior to joining Third Rock Ventures, Reilly was CEO and chairman of the board of Interleukin Genetics, Inc. (2000\u20132006); the executive director of the Eunice Kennedy Shriver Center for Mental Retardation, Inc., a not-for-profit research organization dedicated to helping people with developmental disabilities (1990\u20132000); and an assistant professor at Harvard Medical School. Reilly has served twice (2000 and 2003) as president of the American Society of Law, Medicine, and Ethics. From 1994 to 1997, he served on the Board of Directors of the American Society for Human Genetics. He is a founding fellow of the American College of Medical Genetics. Reilly was a trustee of Cornell University from 2006\u00ac to 2014. He is currently a member of the Board of Overseers of Weill Cornell Medical College, and also serves on the Advisory Council to the Boston University School of Public Health. He is the author of seven books about human genetics and more than 100 articles, many about public policy issues in genetics. His latest (seventh) book,\u00a0<\/span><em>Orphan: The Quest to Save Children with Rare Genetic Disorders<\/em><span>, was published in 2015. Reilly holds an AB from Cornell University, a JD from Columbia University, and an MD from Yale University.<\/span><span><\/div>\n<\/div>\n<\/span><\/p>\n<h5>Elizabeth Olek (SPH\u201902)<\/h5>\n<p>Senior Medical Director, Puma Biotechnology, Inc.<div class=\"bu_collapsible_container \" aria-live=\"polite\" data-customize-animation=\"false\"><h6 class=\"bu_collapsible\" aria-expanded=\"false\"tabindex=\"0\" role=\"button\">Read More<\/h6><div class=\"bu_collapsible_section\" style=\"display: none;\"><img loading=\"lazy\" src=\"https:\/\/www.bu.edu\/sph\/files\/2018\/07\/HEADSHOT-Olek-Web.png\" alt=\"\" class=\"alignleft size-full wp-image-128834\" width=\"100\" height=\"125\" \/><span>Elizabeth Olek is the senior medical director at Puma Biotechnology, Inc., in South San Francisco, California.\u202fOlek served as the senior vice president of clinical development and chief medical officer of Achillion Pharmaceuticals, Inc., after serving at Novartis Pharmaceuticals Corporation as global brand medical director and principal medical science expert in the Infectious Disease, Transplant, and Immunology Group. Prior to that, she served as director of clinical research of InterMune, Inc. and with Genetics Institute\/Wyeth Research. In her various roles, she was responsible for clinical research and the advancement of various infectious disease drug candidates. Olek holds a BS in pharmacy from the University of the Sciences Philadelphia, a DO from the Philadelphia College of Osteopathic Medicine, and an MPH in epidemiology and biostatistics from Boston University School of Public Health.<\/span><span><\/div>\n<\/div>\n<\/span><\/p>\n<hr \/>\n<h5>1:55 p.m. \u2013 2:00 p.m.<\/h5>\n<h5><strong>Closing<\/strong><\/h5>\n<hr \/>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Tuesday, October 2, 2018 8:30 a.m.\u20132 p.m. Hiebert Lounge 72 East Concord Street Boston #BUSPHSymposia Public health aspires to generate the social, economic, and cultural conditions that can create health. This work, by definition, must involve collaboration across sectors. Historically, academic public health has achieved much success partnering with the public sector toward achieving its [&hellip;]<\/p>\n","protected":false},"featured_media":0,"template":"","conversation_topic":[3896],"conversation_date":[3928],"conversation_status":[3515],"_links":{"self":[{"href":"https:\/\/www.bu.edu\/sph\/wp-json\/wp\/v2\/conversation\/124000"}],"collection":[{"href":"https:\/\/www.bu.edu\/sph\/wp-json\/wp\/v2\/conversation"}],"about":[{"href":"https:\/\/www.bu.edu\/sph\/wp-json\/wp\/v2\/types\/conversation"}],"version-history":[{"count":43,"href":"https:\/\/www.bu.edu\/sph\/wp-json\/wp\/v2\/conversation\/124000\/revisions"}],"predecessor-version":[{"id":185771,"href":"https:\/\/www.bu.edu\/sph\/wp-json\/wp\/v2\/conversation\/124000\/revisions\/185771"}],"wp:attachment":[{"href":"https:\/\/www.bu.edu\/sph\/wp-json\/wp\/v2\/media?parent=124000"}],"wp:term":[{"taxonomy":"conversation_topic","embeddable":true,"href":"https:\/\/www.bu.edu\/sph\/wp-json\/wp\/v2\/conversation_topic?post=124000"},{"taxonomy":"conversation_date","embeddable":true,"href":"https:\/\/www.bu.edu\/sph\/wp-json\/wp\/v2\/conversation_date?post=124000"},{"taxonomy":"conversation_status","embeddable":true,"href":"https:\/\/www.bu.edu\/sph\/wp-json\/wp\/v2\/conversation_status?post=124000"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}